Compare Schlumberger NV (SLB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schlumberger NV vs State Street SPDR S&P Biotech ETF — how do they compare? Schlumberger NV trades at $52.24 (market cap $78.08B), while State Street SPDR S&P Biotech ETF trades at $156.65. The key difference: Schlumberger NV pays a 2.24% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Schlumberger NV nearer its low. Which is the better fit depends on your goals.
| SLB | XBI | |
|---|---|---|
Market Cap | $78.08B | — |
Sector | Energy | Broad Market / Factor |
52-Week High | $58.01 | $164.28 |
52-Week Low | $31.72 | $88.79 |
Enterprise Value | $86.81B | — |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLB trades at $52.06, down 3.02% over 24 hours, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $0.55, beating estimates, and maintains strong cash flow from operations of $6.49B in 2025. Revenue trends show resilience despite a slight dip to $35.71B in 2025, with profitability supported by an 8.53% net income margin.
Outlook remains positive with an 84.85% analyst buy rating and a $63.00 consensus price target, implying 21% upside. Risks include Middle East operational challenges and net cash outflows, but growth in digital and offshore segments offers opportunity. The stock's valuation at a P/E of 25.66 is reasonable given earnings momentum.
XBI trades at $159.39, up 0.84% today, with a bullish technical signal from moving averages and a strong 80.2% 1-year return. The ETF holds 155 biotech stocks, benefiting from recent M&A and AI-driven drug discovery trends. Analyst coverage is limited to one hold rating, while institutional interest is evident with Bay Colony Advisors adding a $793,000 position in Q2 2026.
Outlook remains positive due to sector momentum, but risks include high volatility and policy uncertainty. The equal-weight strategy offers upside in bullish cycles, yet investors face elevated drawdowns compared to broader healthcare ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
